Clinical Trial Detail

NCT ID NCT04504669
Title First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca
Indications

Advanced Solid Tumor

cervical cancer

lung small cell carcinoma

head and neck squamous cell carcinoma

clear cell renal cell carcinoma

triple-receptor negative breast cancer

melanoma

lung non-small cell carcinoma

stomach cancer

Therapies

AZD8701 + Durvalumab

AZD8701

Age Groups: adult senior

No variant requirements are available.